CovidChloroV1, Main, Curation, bibRecord, 001433

Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.

Identifieur interne : 001433 ( Main/Curation ); précédent : 001432; suivant : 001434

Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.

Auteurs : Ji Eun Kang [Corée du Sud] ; Sandy Jeong Rhie [Corée du Sud]

Source :

Journal of clinical pharmacy and therapeutics [ 1365-2710 ] ; 2020.

RBID : pubmed:32524645

Descripteurs français

KwdFr :
- Antipaludiques (administration et posologie), Antipaludiques (effets indésirables), Antipaludiques (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Humains (MeSH), Médicaments en essais cliniques (administration et posologie), Médicaments en essais cliniques (effets indésirables), Médicaments en essais cliniques (usage thérapeutique), Relation dose-effet des médicaments (MeSH), Repositionnement des médicaments (MeSH), République de Corée (MeSH), Surveillance des médicaments (MeSH).
MESH :
- administration et posologie : Antipaludiques, Antiviraux, Médicaments en essais cliniques.
- effets indésirables : Antipaludiques, Antiviraux, Médicaments en essais cliniques.
- usage thérapeutique : Antipaludiques, Antiviraux, Médicaments en essais cliniques.
- Humains, Relation dose-effet des médicaments, Repositionnement des médicaments, République de Corée, Surveillance des médicaments.

English descriptors

KwdEn :
- Antimalarials (administration & dosage), Antimalarials (adverse effects), Antimalarials (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), Dose-Response Relationship, Drug (MeSH), Drug Monitoring (MeSH), Drug Repositioning (MeSH), Drugs, Investigational (administration & dosage), Drugs, Investigational (adverse effects), Drugs, Investigational (therapeutic use), Humans (MeSH), Republic of Korea (MeSH).
MESH :
- chemical , administration & dosage : Antimalarials, Antiviral Agents, Drugs, Investigational.
- chemical , adverse effects : Antimalarials, Antiviral Agents, Drugs, Investigational.
- chemical , therapeutic use : Antimalarials, Antiviral Agents, Drugs, Investigational.
- geographic : Republic of Korea.
- drug therapy : COVID-19.
- Dose-Response Relationship, Drug, Drug Monitoring, Drug Repositioning, Humans.

Abstract

WHAT IS KNOWN AND OBJECTIVE

Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID-19. We comment on various drugs currently undergoing such trials to optimize their safe use.

COMMENT

We describe medications used during early COVID-19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient-monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high-dose intravenous immunoglobulin (IVIG).

WHAT IS NEW AND CONCLUSION

Effective therapies are urgently needed to manage COVID-19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up-to-date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.

DOI: 10.1111/jcpt.13199
PubMed: 32524645
PubMed Central: PMC7307068

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001433

Links to Exploration step

pubmed:32524645

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.</title>
<author><name sortKey="Kang, Ji Eun" sort="Kang, Ji Eun" uniqKey="Kang J" first="Ji Eun" last="Kang">Ji Eun Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Ewha Womans University, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>College of Pharmacy, Ewha Womans University, Seoul</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, National Medical Center, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Pharmacy, National Medical Center, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rhie, Sandy Jeong" sort="Rhie, Sandy Jeong" uniqKey="Rhie S" first="Sandy Jeong" last="Rhie">Sandy Jeong Rhie</name>
<affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Ewha Womans University, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>College of Pharmacy, Ewha Womans University, Seoul</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32524645</idno>
<idno type="pmid">32524645</idno>
<idno type="doi">10.1111/jcpt.13199</idno>
<idno type="pmc">PMC7307068</idno>
<idno type="wicri:Area/Main/Corpus">001433</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001433</idno>
<idno type="wicri:Area/Main/Curation">001433</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001433</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.</title>
<author><name sortKey="Kang, Ji Eun" sort="Kang, Ji Eun" uniqKey="Kang J" first="Ji Eun" last="Kang">Ji Eun Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Ewha Womans University, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>College of Pharmacy, Ewha Womans University, Seoul</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, National Medical Center, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Pharmacy, National Medical Center, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rhie, Sandy Jeong" sort="Rhie, Sandy Jeong" uniqKey="Rhie S" first="Sandy Jeong" last="Rhie">Sandy Jeong Rhie</name>
<affiliation wicri:level="1"><nlm:affiliation>College of Pharmacy, Ewha Womans University, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>College of Pharmacy, Ewha Womans University, Seoul</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of clinical pharmacy and therapeutics</title>
<idno type="eISSN">1365-2710</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (administration & dosage)</term>
<term>Antimalarials (adverse effects)</term>
<term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>Dose-Response Relationship, Drug (MeSH)</term>
<term>Drug Monitoring (MeSH)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Drugs, Investigational (administration & dosage)</term>
<term>Drugs, Investigational (adverse effects)</term>
<term>Drugs, Investigational (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Republic of Korea (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antipaludiques (administration et posologie)</term>
<term>Antipaludiques (effets indésirables)</term>
<term>Antipaludiques (usage thérapeutique)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Médicaments en essais cliniques (administration et posologie)</term>
<term>Médicaments en essais cliniques (effets indésirables)</term>
<term>Médicaments en essais cliniques (usage thérapeutique)</term>
<term>Relation dose-effet des médicaments (MeSH)</term>
<term>Repositionnement des médicaments (MeSH)</term>
<term>République de Corée (MeSH)</term>
<term>Surveillance des médicaments (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Drugs, Investigational</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Drugs, Investigational</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>Drugs, Investigational</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Republic of Korea</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Médicaments en essais cliniques</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Médicaments en essais cliniques</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Médicaments en essais cliniques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term>
<term>Drug Monitoring</term>
<term>Drug Repositioning</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Relation dose-effet des médicaments</term>
<term>Repositionnement des médicaments</term>
<term>République de Corée</term>
<term>Surveillance des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>WHAT IS KNOWN AND OBJECTIVE</b>
</p>
<p>Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID-19. We comment on various drugs currently undergoing such trials to optimize their safe use.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>COMMENT</b>
</p>
<p>We describe medications used during early COVID-19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient-monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high-dose intravenous immunoglobulin (IVIG).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>WHAT IS NEW AND CONCLUSION</b>
</p>
<p>Effective therapies are urgently needed to manage COVID-19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up-to-date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32524645</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2710</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>45</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical pharmacy and therapeutics</Title>
<ISOAbbreviation>J Clin Pharm Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.</ArticleTitle>
<Pagination><MedlinePgn>1199-1205</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jcpt.13199</ELocationID>
<Abstract><AbstractText Label="WHAT IS KNOWN AND OBJECTIVE" NlmCategory="OBJECTIVE">Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID-19. We comment on various drugs currently undergoing such trials to optimize their safe use.</AbstractText>
<AbstractText Label="COMMENT" NlmCategory="CONCLUSIONS">We describe medications used during early COVID-19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient-monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high-dose intravenous immunoglobulin (IVIG).</AbstractText>
<AbstractText Label="WHAT IS NEW AND CONCLUSION" NlmCategory="CONCLUSIONS">Effective therapies are urgently needed to manage COVID-19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up-to-date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.</AbstractText>
<CopyrightInformation>© 2020 John Wiley & Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>Ji Eun</ForeName>
<Initials>JE</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-0642-2330</Identifier>
<AffiliationInfo><Affiliation>College of Pharmacy, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pharmacy, National Medical Center, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rhie</LastName>
<ForeName>Sandy Jeong</ForeName>
<Initials>SJ</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0003-2554-3370</Identifier>
<AffiliationInfo><Affiliation>College of Pharmacy, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>2017R1D1A1B03033389</GrantID>
<Agency>Ministry of Education</Agency>
<Country></Country>
</Grant>
<Grant><GrantID>2020R1A2C1009224</GrantID>
<Agency>National Research Foundation of Korea MSIT</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Clin Pharm Ther</MedlineTA>
<NlmUniqueID>8704308</NlmUniqueID>
<ISSNLinking>0269-4727</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">investigational medication</Keyword>
<Keyword MajorTopicYN="N">severe acute respiratory syndrome</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32524645</ArticleId>
<ArticleId IdType="doi">10.1111/jcpt.13199</ArticleId>
<ArticleId IdType="pmc">PMC7307068</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2018 Jan 30;19(1):81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29382391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2016 Jun;48(2):118-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27433382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Oct 01;9(10):e109180</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25271834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2015 Sep;47(3):212-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26483999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15215127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ophthalmology. 2016 Jun;123(6):1386-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26992838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharm Ther. 2020 Oct;45(5):1199-1205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32524645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Infect Dis. 2020 May 8;6(5):909-915</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32125140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 21;382(21):2005-2011</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2010 Nov 04;6(11):e1001176</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21079686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 1994 Sep;13(9):827-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7808855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2018 May 17;10(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001433 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001433 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32524645
   |texte=   Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:32524645" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.

Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki